Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
Rauscher GH, Silva A, Pauls H, Frasor J, Bonini MG, Hoskins K (2017) Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities. Breast Cancer Res Treat. doi:10.​1007/​s10549-017-4166-z PubMed
2.
Grant WB, Peiris AN (2012) Differences in vitamin D status may account for unexplained disparities in cancer survival rates between African and White Americans. Dermatoendocrinology 4:85–94CrossRef
3.
Blackmore KM, Lesosky M, Barnett H, Raboud JM, Vieth R, Knight JA (2008) Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer. Am J Epidemiol 168:915–924CrossRefPubMed
Metadata
Title
Racial disparity in vitamin D status may explain racial disparity in survival from estrogen and progesterone receptor-positive breast cancer
Author
William B. Grant
Publication date
01-07-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4237-1

Other articles of this Issue 1/2017

Breast Cancer Research and Treatment 1/2017 Go to the issue

Review

Ablative Therapies in Metastatic Breast Cancer: A Systematic Review

Preclinical study

Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression

Brief Report

Assessment of the prognostic and discriminating value of the novel bioscore system for breast cancer; a SEER database analysis

Epidemiology

Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors

Clinical trial

Changes in arm tissue composition with slowly progressive weight-lifting among women with breast cancer-related lymphedema

Clinical trial

Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits